- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06189963
Fase I/IIa-studie van SNK01 bij deelnemers met matige ziekte van Alzheimer
Een fase I/IIa-onderzoek om de veiligheid, verdraagbaarheid en verkennende werkzaamheid van SNK01 te evalueren bij deelnemers met een matige ziekte van Alzheimer
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:
- Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion
- Can SNK01 administration improve cognitive assessment scores and biomarkers
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Study Director
- Telefoonnummer: 949-396-6830
- E-mail: trials@nkgenbiotech.com
Studie Locaties
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Z 1G3
- Ingetrokken
- Ottawa Memory Clinic
-
-
-
-
California
-
Glendale, California, Verenigde Staten, 91206
- Werving
- Behavioral Research Specialists, LLC
-
Contact:
- Harry Chung
- Telefoonnummer: (888) 255-5798
- E-mail: harry@brstrials.com
-
Santa Ana, California, Verenigde Staten, 92705
- Werving
- Syrentis Clinical Research
-
Contact:
- Nikole Bo
- Telefoonnummer: 714-542-3008
- E-mail: nbo@syrentis.com
-
Tarzana, California, Verenigde Staten, 91356
- Ingetrokken
- Valiance Clinical Research
-
-
Florida
-
Maitland, Florida, Verenigde Staten, 32751
- Werving
- K2 Medical Research
-
Contact:
- Adaliz Rodriguez
- Telefoonnummer: 407-500-5252
- E-mail: adaliz.rodriguez@k2med.com
-
Orlando, Florida, Verenigde Staten, 32804
- Werving
- AdventHealth Research Institute
-
Contact:
- Ana Chavarro Rendon
- Telefoonnummer: 407-609-9040
- E-mail: cfd-sneuroscienceresearch@adventhealth.com
-
-
New Jersey
-
Newark, New Jersey, Verenigde Staten, 07107
- Werving
- Rutgers Health
-
Contact:
- Kelly Saverino
- Telefoonnummer: 973-972-1268
- E-mail: kcs143@njms.rutgers.edu
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Werving
- Alzheimer's Disease Research Center
-
Contact:
- Laura Wang
- Telefoonnummer: 518-426-0575
- E-mail: lwang@naaresearch.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the participant).
-
Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site. The study partner/caregiver must sign a separate informed consent form which describes their contributions during the study.
-
Patients with diagnosis of Alzheimer's dementia according to the recommendations from the 2011 National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
-
Age 40 to 85 years old.
-
Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient or their legally authorized representative and documented by the study investigator.
-
Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Visit 1 before first administration of the study drug. Females of childbearing potential are defined as those who are not surgically sterile or who are not post-menopausal (i.e.: no menses for at least 1 year). Male and female participants of reproductive potential must also agree to abstinence or use acceptable form(s) of effective contraception during the study and for 30 days after the final dose of the study drug. Acceptable methods of contraception include the following:
- Condoms, sponges, foams, gels, diaphragms, or intrauterine device (IUD).
- Hormonal birth control for 30 days prior to administration of the study drug.
- A vasectomized sexual partner.
-
Positive evidence for a diagnosis of AD via amyloid positron emission tomography (Amyloid PET) of the brain within the past six months.
-
CDR-SB score of ≥ 9.5 and <16.0.
Exclusion Criteria:
- Substantial concomitant cerebrovascular disease defined as Fazekas Grade 3.
- History of a stroke/intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment in the opinion of the investigator.
- Any substance use disorder that has not been in remission for at least 12 months
- Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
- Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without oedema), tachycardia, arrhythmias, uncontrolled hypertension.
- History of cerebrovascular accident or transient ischemic attack (TIA), or unexplainable loss of consciousness within the last year.
- Significant pulmonary disease predisposing to hypoxia.
- Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinically significant heart disease classified as NYHA III or IV.
- Significant liver disease (for example cirrhosis, active hepatitis B and C, primary or metastatic liver neoplasm).
- Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening.
- Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
- Immunological disorder such as per investigator judgement clinically significant allergies, Lupus erythematodes, or scleroderma.
- Uncontrolled/Unstable hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression.
- Neurological disease (such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) and psychiatric disorders (such as schizophrenia, or intellectual disability), or any other disorders impacting cognitive function.
- Unstable/uncontrolled major depression or anxiety within the last 12 months.
- History of seizures in the past three years.
- Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or manifest hyperthyroidism, in the opinion of the investigator.
- Severe renal impairment defined as a GFR < 30 mL/min/1.73 m2 in the screening lab report
- Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any other infection or active systemic disease.
- Currently being treated with anticoagulants (except aspirin at or below a prophylactic dose).
- Participants who are taking medications for AD, like memantine or acetylcholinesterase inhibitors (AChEI) that exceeds the normal recommended dose range or have not achieved a stable dose for the 30 days prior to enrollment.
- Any contraindication for performing a brain MRI and/or Amyloid PET scan.
- Any participant whose safety the investigator considers to be at risk from this trial's intervention.
- Participants with any medically unstable/uncontrolled conditions.
- Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
- Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: SNK01
SNK01 will be administered as an IV infusion Q3W for up to 1 year. |
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug |
|
Placebo-vergelijker: Placebo
Placebo will be administered as an IV infusion Q3W for up to 1 year. |
Sodium Lactate Hartmann's Solution |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with dose-limiting toxicity
Tijdsspanne: 3 weeks
|
DLTs will be assessed by the review of labs, PE and AEs |
3 weeks
|
|
Maximum tolerated dose determination
Tijdsspanne: 3 weeks
|
Determine the maximum tolerated dose based on the evaluation of the number of participants who experience a DLT which will then determine the RP2D. |
3 weeks
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Tijdsspanne: 1 Year
|
Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of CDR-SB
Tijdsspanne: 1 Year
|
Measure changes in cognitive assessment of CDR-SB from baseline |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of MMSE
Tijdsspanne: 1 Year
|
Measure changes in cognitive assessment of MMSE from baseline |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of NPI
Tijdsspanne: 1 Year
|
Measure changes in cognitive assessment of NPI from baseline |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe
Tijdsspanne: 1 Year
|
Measure changes in cognitive assessment of ADCS-ADL-Severe from baseline |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of ADAS-Cog
Tijdsspanne: 1 Year
|
Measure changes in cognitive assessment of ADAS-Cog from baseline |
1 Year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Changes in CSF biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
Tijdsspanne: 1 Year
|
Measure changes in CSF biomarkers as changed from baseline |
1 Year
|
|
Changes in plasma biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
Tijdsspanne: 1 Year
|
Measure changes in Plasma biomarkers as changed from baseline |
1 Year
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- SNK01-AD01
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .